Immunic's Strategic Conference Engagements to Promote Neurologic Disease Therapies and Collaborations

Immunic Inc (IMUX), a biotechnology company at the forefront of developing oral therapies for neurologic diseases, is actively engaging with the medical and investment community through its upcoming participation in several major conferences. This strategic move not only highlights the company's commitment to advancing its innovative approaches but also signifies its dedication to building robust relationships with potential investors and collaborators. The events scheduled for June include key presentations and discussions that are pivotal for the company’s visibility in the competitive biotech landscape.

Engagement at Key Conferences

From June 15-16, Immunic's CEO, Erik Lundgren, and COO, Jason Tardio, engage in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, which can be accessed both in-person in New York and virtually. This event presents a valuable platform for the company to discuss its strategic vision and initiatives, particularly focusing on its lead product candidate, vidofludimus calcium (IMU-838), which is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis. Additionally, a pre-recorded presentation will be available on the conference website, ensuring broader accessibility to their insights.

Expanding Research and Development

Furthermore, during the BIO International Convention in San Diego from June 22-25, Immunic plans to engage in partnering activities that could foster collaborations essential for its growth trajectory. This is complemented by the presentation from Christian Gege, Ph.D., Global Head of Intellectual Property, at the EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 Symposium in Dublin on June 25. His discussion of IMU-856, a selective Sirtuin 6 modulator for gastrointestinal diseases, underscores the company’s focus on expanding its research pipeline beyond neurology.

Concluding Thoughts

Overall, Immunic's strategic participation in these high-profile conferences reflects its proactive approach toward industry engagement and innovation. As the company moves forward with its clinical programs and potential collaborations, stakeholders will be keenly observing how these interactions contribute to fostering advancements in treatment for neurological diseases and beyond.